MAP1LC3A and colorectal carcinoma: It has been reported that dexmedetomidine-treated CRC cells have increased LC3 sites and lysosomal structures to induce autophagy and inhibit the proliferation of CRC, which in turn affects the progression of CRC (Hou and Xu, 2024).